DCMIC
NAUT icon

Decheng Capital Management III (Cayman)’s Nautilus Biotechnolgy NAUT Stock Holding History

Decheng Capital Management III (Cayman)’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-300,000
Closed -$540K – 25
2022
Q4 		$540K Hold
300,000
– – 0.2% 24
2022
Q3 		$636K Hold
300,000
– – 0.23% 25
2022
Q2 		$807K Hold
300,000
– – 0.31% 23
2022
Q1 		$1.3M Buy
+300,000
New +$1.23M 0.4% 22

Other funds holding NAUT

Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return
Amazon.com Inc
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return

Decheng Capital Management III (Cayman)'s NAUT Position: Q1 2023 in Review

Decheng Capital Management III (Cayman) sold out of Nautilus Biotechnolgy (NAUT) in Q1 2023, closing a stake of 300,000 shares — an estimated $540K sold.

Decheng Capital Management III (Cayman) first reported a position in NAUT in Q1 2022 and held it in 4 quarters. The position peaked at $1.3M in Q1 2022. 73 funds tracked by Wall St. Rank hold NAUT as of Q1 2023.

  • Decheng Capital Management III (Cayman) reported no remaining Nautilus Biotechnolgy position as of Q1 2023 after selling out during the quarter.
  • Decheng Capital Management III (Cayman) sold 300,000 Nautilus Biotechnolgy shares in Q1 2023, an estimated $540K.
  • Decheng Capital Management III (Cayman) first reported a position in Nautilus Biotechnolgy in Q1 2022 and held it in 4 quarters.
  • Decheng Capital Management III (Cayman)'s Nautilus Biotechnolgy position peaked at $1.3M in Q1 2022.
  • 73 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q1 2023.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q1 2023, filed 10 May 2023.